Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

The design of novel inhibitors to target BACE1 with reduced cytotoxicity effects is a promising approach to treat Alzheimer's disease (AD). Multiple clinical drugs and antibodies such as AZD3293 and Solanezumab are being tested to investigate their therapeutical potential against AD. The curren...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Mubashir Hassan, Saba Shahzadi, Sung Y. Seo, Hany Alashwal, Nazar Zaki, Ahmed A. Moustafa
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2018-06-01
Collection:Frontiers in Computational Neuroscience
Sujets:
Alzheimer's disease
computational modeling
dynamic simulation
AZD3293
solanezumab
Accès en ligne:https://www.frontiersin.org/article/10.3389/fncom.2018.00034/full
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires